Targeted Adenoviral Gene Therapy for Malignant Glioma

恶性胶质瘤的靶向腺病毒基因治疗

• 批准号: 7406654
• 负责人: MACIEJ S LESNIAK
• 金额: $ 16.51万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-15 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7406654
• 关键词: Adenovirus Vector; Adenoviruses; Adult; Binding Sites; Biomedical Research; Brain Neoplasms; CAR receptor; Cells; Clinical; Clinical Trials; Data; Dose; Education; Exhibits; Fiber; Funding; Future; Gene Delivery; Generations; Genes; Glioblastoma; Glioma; Goals; Grant; Hospitals; Immune; Immune Targeting; Immune response; Integrins; Lead; Malignant Glioma; Malignant Neoplasms; Malignant neoplasm of brain; Modality; Mutation; Neuraxis; Neurosurgical Procedures; Normal Cell; Oncolytic; Operative Surgical Procedures; Organ; Patients; Peptides; Predisposition; Principal Investigator; Publications; Purpose; Radiation therapy; Relative (related person); Research; Research Personnel; Residencies; Resistance; Solid; Specificity; Testing; Time; Tissues; Toxic effect; Translating; Tropism; United States National Institutes of Health; Viral Vector; Virus; base; cancer therapy; day; design; gene therapy; in vivo; integrin beta5; neoplastic cell; neurosurgery; pre-clinical; professor; receptor; research study; success; tumor; vector

DESCRIPTION (provided by applicant): High grade gliomas represent the most common primary malignant tumor of the adult central nervous system. Unfortunately, the median survival after surgical intervention alone is only six months and the addition of radiotherapy can extend this time to only nine months. Consequently, efforts aimed at developing new therapies have focused on new treatment strategies that specifically target tumor cells and spare normal cells. One such modality, gene therapy, has shown promise in the spectrum of agents utilized against brain tumors. The success of gene therapy depends on efficient gene delivery into target cells. Viral vectors, in the form of adenoviruses, have provided one potential means for the delivery of gene therapy. Several studies, however, have demonstrated a relative resistance of brain tumors to adenoviral vectors, a finding that was subsequently attributed to the quantitative deficiency of the primary adenoviral receptor, the Coxsackie Adenovirus Receptor (CAR), on tumor cells. The main purpose of this project is to develop re-targeted adenoviral vectors with the capacity to enhance immune based cancer therapies. The focus of the re-targeting has been the expression of alpha-v-beta3 and alpha-v-beta5 on many solid organ tumors. This project aims to develop second generation adenoviruses with altered tropism for alpha-v-beta3 and alpha-v-beta5 integrins in order to achieve cell-specific targeting of immune-modulatory genes. The principal investigator, Dr. Maciej S. Lesniak, has recently completed his residency in neurological surgery and is currently as Assistant Professor of Neurosurgery at the Johns Hopkins Hospital. Dr. Lesniak immediate goals are to establish a solid research background that will allow him to become an independent investigator. By undertaking this project and furthering his scientific and biomedical research education, Dr. Lesniak hopes to one day translate this research to the clinical setting and the treatment of patients with malignant brain tumors.

描述(由申请人提供)： 高级别胶质瘤是成人中枢神经系统最常见的原发恶性肿瘤。不幸的是，仅手术干预后的中位生存期只有6个月，加上放射治疗，这一时间只能延长到9个月。因此，旨在开发新疗法的努力集中在专门针对肿瘤细胞和备用正常细胞的新治疗策略上。一种这样的方式，基因疗法，在用于治疗脑瘤的药物谱中显示出了希望。基因治疗的成功依赖于有效地将基因输送到靶细胞。以腺病毒形式存在的病毒载体为基因治疗提供了一种潜在的途径。然而，一些研究表明脑肿瘤对腺病毒载体具有相对耐药性，这一发现随后被归因于肿瘤细胞上主要的腺病毒受体柯萨奇病毒受体(CAR)的数量缺陷。该项目的主要目的是开发具有增强基于免疫的癌症治疗能力的重定向腺病毒载体。重新靶向的焦点是许多实体器官肿瘤上α-v-Beta3和α-v-Beta5的表达。该项目旨在发展第二代腺病毒，改变对α-v-Beta3和α-v-Beta5整合素的趋向性，以实现免疫调节基因的细胞特异性靶向。首席研究员Maciej S.Lesniak博士最近完成了他的神经外科住院医师资格，目前是约翰·霍普金斯医院的神经外科助理教授。莱斯尼亚克博士目前的目标是建立一个坚实的研究背景，使他能够成为一名独立的调查员。莱斯尼亚克博士希望，通过实施这一项目并进一步推进他的科学和生物医学研究教育，有一天能将这项研究转化为临床环境和恶性脑瘤患者的治疗。